Blog
RSS FeedPosted by Michael Wonder on 11 Sep 2020
NICE backs Portola's Ondexxya
11 September 2020 - NICE has published the outcome of an appraisal consultation document backing NHS funds for restricted use ...
Posted by Michael Wonder on 11 Sep 2020
Nasal spray medicine for treatment-resistant depression not recommended by NICE
3 September 2020 - Consultation open on draft guidance until Friday 25 September 2020. ...
Posted by Michael Wonder on 03 Sep 2020
Janssen disappointed with second NICE no for Spravato
3 September 2020 - Janssen says it is disappointed with second draft guidance from the National Institute for Health and ...
Posted by Michael Wonder on 02 Sep 2020
NICE green light for immunotherapy Bavencio
2 September 2020 - NICE has now published final guidelines endorsing NHS use of Merck and Pfizer's immunotherapy Bavencio (avelumab) ...
Posted by Michael Wonder on 28 Aug 2020
Kidney cancer charity slams NICE rejection of Keytruda/Inlyta
28 August 2020 - MSD’s Keytruda (pembrolizumab) in combination with Pfizer's Inlyta (axitinib) has been turned down by NICE as ...
Posted by Michael Wonder on 20 Aug 2020
New agreement means NICE recommends combination treatment for some lymphoma patients
20 August 2020 - Hundreds of people with a form of blood cancer will benefit from a new treatment following the ...
Posted by Michael Wonder on 17 Aug 2020
Janssen and others have appealed NICE's decision to reject abiraterone acetate for patients with for high risk hormone-sensitive metastatic prostate cancer
17 August 2020 - The appeal panel will convene on 3 September and 4 September to hear oral representations from the ...
Posted by Michael Wonder on 13 Aug 2020
NICE recommends Adcetris for first-line use for patients with a rare form of non-Hodgkin's lymphoma
12 August 2020 - NICE has published its final guidance on the use of brentuximab vedotin in combination with chemotherapy ...
Posted by Michael Wonder on 06 Aug 2020
NICE supports use of new medicine for patients with malignant disease
5 August 2020 - Treosulphan is used as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation. ...
Posted by Michael Wonder on 05 Aug 2020
NICE publishes draft guidance on the use of a topical gel by patients with a rare cancer
5 August 2020 - The Department of Health and Social Care has asked NICE to produce guidance on using chlormethine gel ...
Posted by Michael Wonder on 31 Jul 2020
NICE recommends Bavencio (avelumab) in combination with axitinib for first-line treatment of adult patients with advanced renal cell carcinoma
31 July 2020 - This is the first combination of an immunotherapy with a targeted antiangiogenic therapy to be recommended ...
Posted by Michael Wonder on 30 Jul 2020
NICE rejects NHS funding for Kyowa Kirin's Poteligeo
30 July 2020 - NICE is not recommending NHS funding for Kyowa Kirin's Poteligeo (mogamulizumab) as a treatment for mycosis ...
Posted by Michael Wonder on 11 Jul 2020
NICE backing for Takeda's Adcetris for rare lymphoma
10 July 2020 - Takeda's Adcetris (brentuximab vedotin) has won the backing of the National Institute for Health and Care ...
Posted by Michael Wonder on 25 Jun 2020
NICE draft guidance does not recommend siponimod for treating secondary progressive multiple sclerosis
25 June 2020 - NICE has today issued draft guidance for public consultation which does not recommend siponimod (Mayzent, Novartis) for ...
Posted by Michael Wonder on 25 Jun 2020
Cancer patients to benefit from new histology independent treatment
25 June 2020 - Entrectinib (Rozlytrek, Roche), a revolutionary treatment for a range of cancers, is the second histology independent drug ...